Tharimmune, Inc. (THAR) Stock Grade

About Tharimmune, Inc.'s fundamentals

Tharimmune is a biotech company with a market capitalization of $139.9 million that reported flat revenue growth year-over-year at 0.0% and posted a net loss in its latest annual statement, resulting in a 0.0% net margin. The company does not pay a dividend, which is typical for early-stage biotechnology firms that prioritize reinvesting capital into research and development rather than returning cash to shareholders. Traditional valuation metrics like P/E ratio and return on equity are not applicable given the company's unprofitability.